| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000035659 |
| Receipt No. | R000040611 |
| Scientific Title | Effects of alkalization therapy on chemotherapy in metastatic or recurrent pancreatic cancer, retrospective study |
| Date of disclosure of the study information | 2019/01/24 |
| Last modified on | 2020/01/31 (Ver. 12) |
| Basic information | ||
| Public title | Effects of alkalization therapy on chemotherapy in metastatic or recurrent pancreatic cancer, retrospective study | |
| Acronym | Alkalization therapy with chemotherapy in advanced pancreatic cancer | |
| Scientific Title | Effects of alkalization therapy on chemotherapy in metastatic or recurrent pancreatic cancer, retrospective study | |
| Scientific Title:Acronym | Alkalization therapy with chemotherapy in advanced pancreatic cancer | |
| Region |
|
|
| Condition | |||
| Condition | Pancreatic cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | Our study purpose is to investigate the effect of alkalization therapy on chemotherapy in metastatic or recurrent pancreatic cancer patients. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Overall survival (OS) from diagnosis or recurrence
OS from the start of alkalization therapy Urine pH before and after alkalization therapy |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with metastatic or recurrent pancreatic cancer who were treated at the Karasuma Wada Clinic between April 2015 and December 2017.
Patients who received alkalization therapy. Patients who agreed written informed consent. |
|||
| Key exclusion criteria | Patients who could not follow the alkalization therapy and/or visited our clinic less than 3 times. | |||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Japanese Society on Inflammation and Metabolism in Cancer | ||||||
| Division name | Japanese Society on Inflammation and Metabolism in Cancer, working group | ||||||
| Zip code | 604-0842 | ||||||
| Address | 119 Nishioshikouji-cho, Higashinotouin-nishiiru, Oshikouji-street, Nakagyo-ku, Kyoto 604-0842, Japan | ||||||
| TEL | +81-75-223-3223 | ||||||
| reo-h@nifty.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Japanese Society on Inflammation and Metabolism in Cancer | ||||||
| Division name | Japanese Society on Inflammation and Metabolism in Cancer, working group | ||||||
| Zip code | 604-0842 | ||||||
| Address | 119 Nishioshikouji-cho, Higashinotouin-nishiiru, Oshikouji-street, Nakagyo-ku, Kyoto 604-0842, Japan | ||||||
| TEL | +81-75-223-3223 | ||||||
| Homepage URL | |||||||
| reo-h@nifty.com | |||||||
| Sponsor | |
| Institute | Japanese Society on Inflammation and Metabolism in Cancer |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japanese Society on Inflammation and Metabolism in Cancer |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | The Japan-Multinational Trial Organization |
| Address | 2-14-10-3F Marunouchi, Naka-ku, Nagoya, Aichi |
| Tel | 052-218-3301 |
| info@jmto.org | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | http://www.scim.or.jp |
| Publication of results | Unpublished |
| Result | |||||||
| URL related to results and publications | none | ||||||
| Number of participants that the trial has enrolled | 28 | ||||||
| Results | The mean urine pH was significantly higher after the alkalization therapy (6.85 +- 0.74 vs. 6.39 +- 0.92; p < 0.05). The median overall survival from the start of alkalization therapy of the patients with high urine pH (< 7.0) was significantly longer than those with low urine pH (<= 7.0)(16.1 vs. 4.7 months; p < 0.05). |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | The patients analyzed included 15 men and 13 women, and the mean age at the start of the alkalization therapy was 63.6 (range, 47 to 82) years. Daily living ability of each patient was evaluated according to the Eastern Cooperative Oncology Group scale of Performance Status (PS). Two patients had PS 0, 24 had PS 1, and 1 each had PS 2 and 3. Nineteen patients were clinical stage IV and 9 had recurrent disease. Twenty-three patients had received chemotherapy before their first visit to our clinic, whereas 5 had not. Twenty out of the 28 patients took supplementary bicarbonate. Patient characteristics are presented in Table 1. |
||||||
| Participant flow | A total of 50 patients with metastatic or recurrent pancreatic cancer were treated at the Karasuma Wada Clinic between April 2015 and December 2017. Alkalization therapy was initiated in all patients. If patients refused to follow an alkaline diet owing to their dietary preference, they were excluded from the study population. Therefore, 22 patients who did not follow the alkalization therapy or visited our clinic less than 3 times were excluded from the study. Finally, 28 pancreatic cancer patients who were given alkalization therapy together with chemotherapy were analyzed. |
||||||
| Adverse events | no special notes |
||||||
| Outcome measures | Data were analyzed on June 30, 2019. The mean urine pH of each patient was compared using the paired t-test between before and after alkalization therapy. OS from either the time of diagnosis or recurrence and the start of alkalization therapy was calculated using Kaplan-Meier estimates, and compared between patients with a urine pH of 7.0 or less and those with a urine pH of higher than 7.0. OS from the start of the alkalization therapy was also compared between patients with a urine delta-pH of 1.0 or less and those with a urine delta-pH of more than 1.0. OS from the time of initiation of the alkalization therapy were also compared among patients with a urine delta-pH of 0 or less, those with a delta-pH of more than 0 but less than or equal to 1.0, and those with a delta-pH of more than 1.0. Urine delta-pH was calculated by subtracting the mean urine pH before alkalization therapy from the mean urine pH after alkalization therapy. Mean data set values were presented with +- standard deviation. All p-values were two-sided and p-values of less than 0.05 were considered to indicate a statistically significant difference between two groups. |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | This study was retrospectively conducted to investigate the effect of alkalization therapy on chemotherapy in advanced pancreatic cancer patients. Currently, data analysis is in progress.
In addition, this study is comprehensively included in "Investigation for survival factors of cancer patients analyzed by the data science method" approved by IRB of the JMTO. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000040611 |